Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2 |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | thyroid cancer |
| ICD-0-3 | C73.9 |
| Methods | qPCR, Western blot, RNAi, Luciferase reporter assays, other |
| Sample | PTC paraffin tissues and cell lines (TPC-1 and K-1) |
| Expression Pattern | up-regulated |
| Function Description | Mechanistically, estradiol (E2) significantly promotes H19 transcription via ER? and elevates H19 expression. Silencing of H19 inhibits E2-induced sphere formation ability. Furthermore, H19 acting as a competitive endogenous RNA sequesters miRNA-3126-5p to reciprocally release ER? expression. ER? depletion reverses H19-induced stem-like properties upon E2 treatment. Appropriately, ER? is upregulated in PTC tissue specimens. Notably, aspirin attenuates E2-induced cancer stem-like traits through decreasing both H19 and ER? expression. |
| Pubmed ID | 30389909 |
| Year | 2018 |
| Title | Estrogen receptor ? upregulated by lncRNA-H19 to promote cancer stem-like properties in papillary thyroid carcinoma. |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for thyroid cancer | OMIM COSMIC |